Pexacerfont

Pexacerfont is a drug that was developed by Bristol-Myers Squibb for the treatment of anxiety disorders. It is a corticotropin-releasing hormone receptor 1 antagonist, which means it blocks the action of the hormone corticotropin-releasing hormone (CRH) at its receptor. CRH is involved in the body's response to stress, and it is thought that blocking its action could be beneficial in conditions such as anxiety disorders.

History

Pexacerfont was developed by Bristol-Myers Squibb in the early 2000s. The drug was tested in clinical trials for the treatment of anxiety disorders, but development was discontinued in 2008. The reasons for the discontinuation are not publicly known.

Mechanism of action

Pexacerfont is a corticotropin-releasing hormone receptor 1 antagonist. This means it blocks the action of the hormone corticotropin-releasing hormone at its receptor. CRH is involved in the body's response to stress, and it is thought that blocking its action could be beneficial in conditions such as anxiety disorders.

Clinical trials

Pexacerfont was tested in clinical trials for the treatment of anxiety disorders. However, the results of these trials have not been publicly disclosed, and the development of the drug was discontinued in 2008.

See also

• Bristol-Myers Squibb
• Anxiety disorder
• Corticotropin-releasing hormone
• Corticotropin-releasing hormone receptor 1

‎